New combo therapy aims to outsmart hodgkin lymphoma

NCT ID NCT07209059

Recruiting now Disease control Sponsor: National Research Center for Hematology, Russia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new way to treat advanced Hodgkin lymphoma by combining the immunotherapy drug nivolumab with chemotherapy. Doctors use PET scans early in treatment to see how well it's working and adjust therapy accordingly. The goal is to improve outcomes while reducing side effects. About 30 adults aged 18 to 60 with newly diagnosed advanced Hodgkin lymphoma will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HODGKIN LYMPHOMA HODGKIN DISEASE HODGKIN LYMPHOMA

Contacts and locations

Locations

National Medical Research Center for Hematology
RECRUITING

Moscow, 125167, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.